Ukrainian plant halts supplies of vital anaesthetic drug to Russia

“We can’t re-register the price of this drug. At the moment, we simply can no longer supply it at the same price, this would mean that we are working at a loss,” Natalia Vorona, a representative of the plant said. The company also stressed that this is in no way connected with politics. "Our refusal to supply mesatonum to Russia is not a political stance. We want to work with Russia, as any commercial enterprise we want to make profit. And it no longer possible under the previous conditions,” she emphasized.